Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02513459
Registration number
NCT02513459
Ethics application status
Date submitted
30/07/2015
Date registered
31/07/2015
Date last updated
24/04/2020
Titles & IDs
Public title
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Query!
Scientific title
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Query!
Secondary ID [1]
0
0
2015-001834-15
Query!
Secondary ID [2]
0
0
M15-989
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Risankizumab 600 mg IV
Treatment: Drugs - Risankizumab 180 mg SC
Experimental: Risankizumab - Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Treatment: Drugs: Risankizumab 600 mg IV
Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
Treatment: Drugs: Risankizumab 180 mg SC
Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [1]
0
0
A treatment emergent adverse event was defined as an event that occurred or worsened on or after the first dose of study drug through 140 days after the last dose in the current study for participants not rolling over into M16-000 Sub-study 3 or until the first dose of study drug in NCT03105102. All treatment-emergent serious and nonserious adverse events were collected, whether elicited or spontaneously reported by the participant.
Query!
Timepoint [1]
0
0
From the time of study drug administration until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Remission by Visit
Query!
Assessment method [1]
0
0
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score < 150.
Query!
Timepoint [1]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Response by Visit
Query!
Assessment method [2]
0
0
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical response is defined as CDAI score < 150 or a reduction from baseline of at least 100 points. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Query!
Timepoint [2]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Remission by Visit
Query!
Assessment method [3]
0
0
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency [SF] plus abdominal pain [AP] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Remission is defined as PRO-2 score < 75.
Query!
Timepoint [3]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Response by Visit
Query!
Assessment method [4]
0
0
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency [SF] plus abdominal pain [AP] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. PRO-2 response is defined as a decrease from baseline of 50 points or more. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Query!
Timepoint [4]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission by Visit
Query!
Assessment method [5]
0
0
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Remission is defined as a score of 4 or less, by visit (or for participants with initial isolated ileitis a score of 2 or less).
Query!
Timepoint [5]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Response by Visit
Query!
Assessment method [6]
0
0
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Response is defined as a score of 7 or less (or for participants with initial isolated ileitis > 50% reduction from baseline). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Query!
Timepoint [6]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Mucosal Healing by Visit
Query!
Assessment method [7]
0
0
Mucosal healing is defined as Crohn's Disease Endoscopy Index of Severity (CDEIS) ulcerations sub-score (deep ulceration, superficial ulceration, ulcerated stenosis) of 0 as evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The overall CDEIS score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.
Query!
Timepoint [7]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving Deep Remission by Visit
Query!
Assessment method [8]
0
0
Deep remission is defined as clinical remission (CDAI < 150) and CDEIS remission (CDEIS score of 4 or less, by visit or for participants with initial isolated ileitis a score of 2 or less).
Query!
Timepoint [8]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission by Visit
Query!
Assessment method [9]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ remission is defined as IBDQ total score > 170 points.
Query!
Timepoint [9]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [10]
0
0
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Response by Visit
Query!
Assessment method [10]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ response is defined as increase in IBDQ total score >16 points from baseline. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Query!
Timepoint [10]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [11]
0
0
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) by Visit
Query!
Assessment method [11]
0
0
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Query!
Timepoint [11]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [12]
0
0
Mean Change From Baseline in Patient Reported Outcome 2 (PRO-2) Scores by Visit
Query!
Assessment method [12]
0
0
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency [SF] plus abdominal pain [AP] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Query!
Timepoint [12]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [13]
0
0
Mean Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) by Visit
Query!
Assessment method [13]
0
0
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Query!
Timepoint [13]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [14]
0
0
Mean Change From Baseline in Simple Endoscopic Score (SES-CD) by Visit
Query!
Assessment method [14]
0
0
SES-CD is calculated based the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Query!
Timepoint [14]
0
0
Weeks 0, 48, 104, 152, and 200
Query!
Secondary outcome [15]
0
0
Mean Change From Baseline in Stool Frequency (SF) By Visit
Query!
Assessment method [15]
0
0
Participants were asked to record the frequency of liquid stools on a daily basis. The number of liquid stools in the prior 7 days was summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Query!
Timepoint [15]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [16]
0
0
Mean Change From Baseline in Abdominal Pain (AP) Score By Visit
Query!
Assessment method [16]
0
0
Participants were asked to rate and record daily abdominal pain on a scale of 0 to 3 [none (0), mild (1), moderate (2) and severe (3)]. The ratings in the prior 7 days were summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Query!
Timepoint [16]
0
0
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Query!
Secondary outcome [17]
0
0
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score by Visit
Query!
Assessment method [17]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Query!
Timepoint [17]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [18]
0
0
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain Score by Visit
Query!
Assessment method [18]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Query!
Timepoint [18]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [19]
0
0
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic System Domain Score by Visit
Query!
Assessment method [19]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Query!
Timepoint [19]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [20]
0
0
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score by Visit
Query!
Assessment method [20]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Query!
Timepoint [20]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [21]
0
0
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score by Visit
Query!
Assessment method [21]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Query!
Timepoint [21]
0
0
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Query!
Secondary outcome [22]
0
0
Mean Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) by Visit
Query!
Assessment method [22]
0
0
Concentration of serum high-sensitivity C-reactive Protein (hs-CRP) was analyzed by a central laboratory. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response, and higher levels indicate more inflammation. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Query!
Timepoint [22]
0
0
Weeks 0, 8, 24, 40, 56, 72, 88, 104, 120, 128, 136, 152, 160, 176, and 184
Query!
Secondary outcome [23]
0
0
Mean Change From Baseline in Fecal Calprotectin (FCP) Profile by Visit
Query!
Assessment method [23]
0
0
Fecal calprotectin (FCP) is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Stool samples were analyzed by a central laboratory for fecal calprotectin levels. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Query!
Timepoint [23]
0
0
Weeks 0, 24, 56, 88, 120, 152, and 184
Query!
Eligibility
Key inclusion criteria
- Participants with Crohn's disease, who had successfully completed the preceding trial
NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Successful treatment
is defined as:
1. Completion of period 2 in 1311.6 with a clinical response (drop in Crohn's
Disease Activity Index (CDAI) from baseline by =100) but no remission (CDAI <
150) at Visit E1; or
2. Completion of period 3 in 1311.6 with a clinical response (drop in CDAI from
baseline by =100) and/or remission (CDAI < 150) at Visit E5; or
3. Completion of period 2 or 3 in 1311.6 per protocol with a clinical response or
remission before initiation of 1311.20 can roll-over either directly if that
response/remission is maintained or through an open-label i.v. re-induction phase
if they have lost their previous response/remission.
- Female participants:
1. Women of childbearing potential (not surgically sterilized and between menarche
and 1 year postmenopause), that, if sexually active agree to use one of the
appropriate medically accepted methods of birth control in addition to the
consistent and correct use of a condom from date of screening until 20 weeks
after last administration of study medication. Medically accepted methods of
contraception are: ethinyl estradiol containing contraceptives, diaphragm with
spermicide substance, and intrauterine device, or
2. Surgically sterilized female participants with documentation of prior
hysterectomy, tubal ligation or complete bilateral oophorectomy, or
3. Postmenopausal women with postmenopausal is defined as permanent cessation >/=1
year of previously occurring menses, and
4. Negative serum ß-Human Chorionic Gonadotrophin test at screening and urine
pregnancy test prior to randomization.
- Male participants:
1. Who are documented to be sterile, or
2. Who consistently and correctly use effective method of contraception (i.e.
condoms) during the study and 20 weeks after last administration of study
medication.
- Be able to adhere to the study visit schedule and other protocol requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participants who were not compliant with key study procedures (colonoscopy, treatment
compliance, endpoint assessment, contraception measures) in preceding trial 1311.6
- Participants who could not tolerate risankizumab (BI 655066/ ABBV-066) treatment for
tolerability or safety reasons in the preceding trial
- Are pregnant, nursing, or planning pregnancy while enrolled in the study, or within 20
weeks after receiving the last dose of study medication.
- Participants must agree not to receive a live virus or bacterial or Bacille
Calmette-Guérin vaccination during the study or up to 12 months after the last
administration of study drug.
- Participants who have developed malignancy, or suspicion of active malignant disease
during the preceding trial
- Are intending to participate in any other study using an investigational agent or
procedure during participation in this study.
- Cannot adhere to the concomitant medication requirements
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/06/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
65
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Maryland
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Michigan
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Bruxelles-Capitale
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Liege
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Bonheiden
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Brussels
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Kortrijk
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Leuven
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Roeselare
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Ontario
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Bayern
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Hannover
Query!
Country [13]
0
0
Korea, Republic of
Query!
State/province [13]
0
0
Daegu Gwang Yeogsi
Query!
Country [14]
0
0
Korea, Republic of
Query!
State/province [14]
0
0
Seoul Teugbyeolsi
Query!
Country [15]
0
0
Korea, Republic of
Query!
State/province [15]
0
0
Seoul
Query!
Country [16]
0
0
Netherlands
Query!
State/province [16]
0
0
Noord-Holland
Query!
Country [17]
0
0
Netherlands
Query!
State/province [17]
0
0
Maastricht
Query!
Country [18]
0
0
Poland
Query!
State/province [18]
0
0
Warsaw
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Wroclaw
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Barcelona
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Madrid
Query!
Country [22]
0
0
United Kingdom
Query!
State/province [22]
0
0
London, City Of
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Cambridge
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Leeds
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
Newcastle Upon Tyne
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Boehringer Ingelheim
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study was to investigate long-term safety of risankizumab (BI
655066/ABBV-066) in participants with moderately to severely active Crohn's disease who
showed a clinical response or remission on previous treatment with risankizumab in Study
NCT02031276 (BI trial 1311.6/ AbbVie M15-993) and were now receiving long-term treatment.
Additional objectives of this study were to further investigate long-term efficacy,
tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of risankizumab.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02513459
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
AbbVie Inc.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02513459
Download to PDF